AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21986118 — intervention group
Group type: COMPARATOR
Intervention: OPCAB alone
Number of subjects: 232
Study 19383882 — intervention group
Group type: EXPERIMENTAL
Intervention: Special Intervention (SI)
Number of subjects: 174
Study 19383882 — intervention group
Group type: COMPARATOR
Intervention: Minimal Intervention (MI)
Number of subjects: 174
Study 17875652 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenation (ECMO)
Number of subjects: 106
Study 17875652 — intervention group
Group type: COMPARATOR
Intervention: Control group from original UK ECMO trial
Number of subjects: 106
Study 15015441 — intervention group
Group type: EXPERIMENTAL
Intervention: Qingre Cuochuang tablet (QCT)
Number of subjects: 60
Study 15015441 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (including antisterone, tetracycline, and metronidazole)
Number of subjects: 60
Study 11720460 — intervention group
Group type: EXPERIMENTAL
Intervention: Question prompt sheet provided to patients prior to consultation
Number of subjects: 318
Study 11720460 — intervention group
Group type: EXPERIMENTAL
Intervention: Question prompt sheet used proactively by the doctor
Number of subjects: 318
Study 11720460 — intervention group
Group type: COMPARATOR
Intervention: Question prompt sheet provided to patients
Number of subjects: 318
Study 9137156 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed technique (primary closure with interrupted vertical mattress skin sutures)
Number of subjects: 61
Study 9137156 — intervention group
Group type: COMPARATOR
Intervention: Open technique (conventional packing)
Number of subjects: 61
Study 9137156 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed technique
Number of subjects: 61
Study 8108758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryotherapy (using liquid nitrogen)
Number of subjects: 86
Study 8108758 — intervention group
Group type: COMPARATOR
Intervention: Trichloracetic acid
Number of subjects: 86
Study 3685399 — intervention group
Group type: EXPERIMENTAL
Intervention: Mefenamic acid, 500 mg three times daily during menses (n = 8)
Number of subjects: 30
Study 3685399 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone-impregnated coil releasing 65 micrograms progesterone daily (n = 8)
Number of subjects: 30
Study 3685399 — intervention group
Group type: EXPERIMENTAL
Intervention: Danazol, 200 mg daily (n = 6)
Number of subjects: 30
Study 3685399 — intervention group
Group type: EXPERIMENTAL
Intervention: Norethisterone, 5 mg twice daily from day 15‐25 of the cycle (n = 8)
Number of subjects: 30
Study 29609480 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled yoga intervention (high, moderate, low frequency)
Number of subjects: 375
Study 29609480 — intervention group
Group type: COMPARATOR
Intervention: Guided walking
Number of subjects: 375
Study 29609480 — intervention group
Group type: COMPARATOR
Intervention: Health education
Number of subjects: 375
Study 29609480 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate frequency yoga
Number of subjects: 375
Study 29609480 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency yoga
Number of subjects: 375
Study 29609480 — intervention group
Group type: EXPERIMENTAL
Intervention: Low frequency yoga
Number of subjects: 375
Study 31435739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium Maruishi (0.9 mg/kg)
Number of subjects: 60
Study 31435739 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium MSD (0.9 mg/kg)
Number of subjects: 60
Study 31435739 — intervention group
Group type: EXPERIMENTAL
Intervention: Rocuronium Maruishi
Number of subjects: 60
Study 31435739 — intervention group
Group type: COMPARATOR
Intervention: Rocuronium MSD
Number of subjects: 60
Study 28740251 — intervention group
Group type: COMPARATOR
Intervention: DTS shape 'C'
Number of subjects: 300
Study 28740251 — intervention group
Group type: EXPERIMENTAL
Intervention: DTS shape '1'
Number of subjects: 300
Study 28740251 — intervention group
Group type: COMPARATOR
Intervention: DTS shape 'Г'
Number of subjects: 300
Study 25733160 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint engagement
Number of subjects: 25
Study 23914911 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-alternating vibration (SAV) training for 9 weeks, 3 sessions per week, 10 x 15-second isometric contractions with 30-second active rest on SAV plate (acceleration = 0.91-16.3g)
Number of subjects: 21
Study 23914911 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 21
Study 21297502 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 10305
Study 21297502 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10305
Study 19471183 — intervention group
Group type: EXPERIMENTAL
Intervention: Yi-Gan San (YGS) at an average daily dosage of 6.7 +/- 2.5 g (range, 2.5-7.5 g)
Number of subjects: 34
Study 19471183 — intervention group
Group type: COMPARATOR
Intervention: Control group (YGS-free)
Number of subjects: 34
Study 19471183 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 16505594 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (500 mg/day)
Number of subjects: 36
Study 16505594 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 36
Study 14704543 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Flux implant
Number of subjects: 20
Study 14704543 — intervention group
Group type: COMPARATOR
Intervention: Healon GV
Number of subjects: 20
Study 11445760 — intervention group
Group type: EXPERIMENTAL
Intervention: CHAMPS intervention to increase physical activity
Number of subjects: 249
Study 11445760 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 249
Study 9744846 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered questionnaires (SAQs)
Number of subjects: 1877
Study 9744846 — intervention group
Group type: COMPARATOR
Intervention: Interviewer questioning
Number of subjects: 1877
Study 7851034 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pump flow rate of 200 cc/min
Number of subjects: 16
Study 7851034 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pump flow rate of 500 cc/min
Number of subjects: 16
Study 7851034 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pump flow rates (QB)
Number of subjects: 16
Study 7851034 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-gauge needles
Number of subjects: 16
Study 7851034 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pump flow rates beyond 300 cc/min
Number of subjects: 16
Study 3289598 — intervention group
Group type: COMPARATOR
Intervention: Atenolol 50 mg twice daily alone
Number of subjects: 25
Study 3289598 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg plus nifedipine 20 mg each twice daily
Number of subjects: 25
Study 3289598 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg plus nifedipine 40 mg each twice daily
Number of subjects: 25
Study 29947328 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care with pressure garments
Number of subjects: 88
Study 29947328 — intervention group
Group type: COMPARATOR
Intervention: Standard care comprising scar management techniques (massage, moisturiser, silicone treatment, stretching)
Number of subjects: 88
Study 28753161 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week prescribed home-based exercise intervention (INT; n = 13) - 4 × 45-min moderate-intensity arm-crank exercise sessions per week
Number of subjects: 21
Study 28753161 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON; n = 8)
Number of subjects: 21
Study 28753161 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week prescribed home-based exercise intervention (INT; n = 13)
Number of subjects: 21
Study 25201759 — intervention group
Group type: EXPERIMENTAL
Intervention: Wildflower honey and milk mixture (10ml honey + 90ml milk) for three evenings
Number of subjects: 134
Study 25201759 — intervention group
Group type: COMPARATOR
Intervention: Dextromethorphan (DM) or Levodropropizine (LDP) adjusted for age
Number of subjects: 134
Study 23457535 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous combination antiretroviral therapy (cART)
Number of subjects: 144
Study 21273177 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent docetaxel (75 mg/m² I.V.) followed by bortezomib (1.6 mg/m² I.V. on days 1 and 8)
Number of subjects: 81
Study 21273177 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential docetaxel (75 mg/m² I.V.) followed by bortezomib (1.6 mg/m² I.V. on days 2 and 8)
Number of subjects: 81
Study 21273177 — intervention group
Group type: COMPARATOR
Intervention: Both arms (CON and SEQ)
Number of subjects: 81
Study 19446148 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg monthly oral ibandronate
Number of subjects: 1760
Study 19446148 — intervention group
Group type: COMPARATOR
Intervention: 70 mg weekly oral alendronate
Number of subjects: 1760
Study 19446148 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 1760
Study 16368347 — intervention group
Group type: EXPERIMENTAL
Intervention: Glyceril‐trinitrate/verapamil (GV) solution
Number of subjects: 100
Study 16368347 — intervention group
Group type: EXPERIMENTAL
Intervention: Papaverine
Number of subjects: 100
Study 16368347 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control)
Number of subjects: 100
Study 15197428 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg intra-articular ketorolac
Number of subjects: 80
Study 15197428 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cc intra-articular bupivacaine 0.25%
Number of subjects: 80
Study 15197428 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg intra-articular morphine diluted in 10 cc saline
Number of subjects: 80
Study 15197428 — intervention group
Group type: COMPARATOR
Intervention: 10 cc saline
Number of subjects: 80
Study 11071343 — intervention group
Group type: COMPARATOR
Intervention: Traditional care system using a surfactant cleaner
Number of subjects: 66
Study 11071343 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step chemical care system
Number of subjects: 66
Study 11071343 — intervention group
Group type: COMPARATOR
Intervention: Traditional method of computing the BOZR
Number of subjects: 66
Study 11071343 — intervention group
Group type: COMPARATOR
Intervention: Corneal topometry
Number of subjects: 66
Study 11071343 — intervention group
Group type: EXPERIMENTAL
Intervention: Newly developed guide for TD selection
Number of subjects: 66
Study 11071343 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall success rate of fitting high Dk RGP contact lenses
Number of subjects: 66
Study 9176662 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Total (triclosan/copolymer/SLS/propylene glycol)
Number of subjects: 19
Study 9176662 — intervention group
Group type: EXPERIMENTAL
Intervention: Solidox G (triclosan/zinc citrate/SLS/polyethylene glycol)
Number of subjects: 19
Study 9176662 — intervention group
Group type: EXPERIMENTAL
Intervention: Solidox F (SLS/polyethylene glycol)
Number of subjects: 19
Study 9176662 — intervention group
Group type: EXPERIMENTAL
Intervention: Zendium (non‐ionic detergent)
Number of subjects: 19
Study 2030189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive therapy plus standard inpatient treatment (pharmacotherapy and milieu management)
Number of subjects: 39
Study 2030189 — intervention group
Group type: COMPARATOR
Intervention: Standard inpatient treatment (pharmacotherapy and milieu management)
Number of subjects: 39
Study 7021992 — intervention group
Group type: EXPERIMENTAL
Intervention: Caerulein (20 ng/kg) injected intravenously before oral glucose load
Number of subjects: 17
Study 7021992 — intervention group
Group type: COMPARATOR
Intervention: Control tests without caerulein application
Number of subjects: 17
Study 29508046 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial nerve stimulation (GTNS)
Number of subjects: 40
Study 29508046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training associated with behavioral therapy (GPFMT)
Number of subjects: 40
Study 28692723 — intervention group
Group type: EXPERIMENTAL
Intervention: Deutetrabenazine
Number of subjects: 37
Study 28718495 — intervention group
Group type: COMPARATOR
Intervention: Single HIV and single syphilis rapid diagnostic tests (Arm A)
Number of subjects: 2214
Study 28718495 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual HIV and syphilis rapid diagnostic tests (Arm B)
Number of subjects: 2214
Study 22947108 — intervention group
Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 20
Study 22947108 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Help CBT
Number of subjects: 20
Study 21912128 — intervention group
Group type: EXPERIMENTAL
Intervention: Twice weekly supervised brushing with a self-applied gel containing 12,500 ppm fluoride
Number of subjects: 1075
Study 21912128 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly supervised use of the gel
Number of subjects: 1075
Study 21912128 — intervention group
Group type: COMPARATOR
Intervention: Usual oral hygiene care (Control)
Number of subjects: 1075
Study 21912128 — intervention group
Group type: EXPERIMENTAL
Intervention: Gel applications (at least 60 times over 2 years)
Number of subjects: 1075
Study 19239660 — intervention group
Group type: EXPERIMENTAL
Intervention: Salmeterol/fluticasone propionate (SFC) 50/100 microg bd
Number of subjects: 321
Study 19239660 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone propionate (FP) 200 microg bd
Number of subjects: 321
Study 16681480 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone propionate (2 mg)
Number of subjects: 10
Study 16681480 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 15566420 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg sumatriptan
Number of subjects: 24
Study 11406907 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose perindopril 2 mg plus indapamide 0.625 mg (P/I)
Number of subjects: 277
Study 11406907 — intervention group
Group type: COMPARATOR
Intervention: Losartan 50 mg (L50)
Number of subjects: 277
Study 9728841 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine
Number of subjects: 20
Study 9728841 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution (saline)
Number of subjects: 20
Study 7876403 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone sodium succinate (40 mg, 100 mg, 250 mg, 500 mg)
Number of subjects: 29
Study 7876403 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone suleptanate (40 mg, 100 mg, 250 mg, 500 mg)
Number of subjects: 29
Study 7876403 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both prodrugs
Number of subjects: 29
Study 3277436 — intervention group
Group type: EXPERIMENTAL
Intervention: carteolol 1%
Number of subjects: 98
Study 3277436 — intervention group
Group type: COMPARATOR
Intervention: timolol 0.25%
Number of subjects: 98
Study 29744608 — intervention group
Group type: EXPERIMENTAL
Intervention: TPB-based educational program administered over 1 month
Number of subjects: 120
Study 29744608 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 120
Study 27993154 — intervention group
Group type: EXPERIMENTAL
Intervention: Stempeucel® (25 million cells)
Number of subjects: 60
Study 27993154 — intervention group
Group type: COMPARATOR
Intervention: Stempeucel® (50 million cells)
Number of subjects: 60
Study 27993154 — intervention group
Group type: COMPARATOR
Intervention: Stempeucel® (75 million cells)
Number of subjects: 60
Study 27993154 — intervention group
Group type: COMPARATOR
Intervention: Stempeucel® (150 million cells)
Number of subjects: 60
Study 27993154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24727884 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 11080
Study 24727884 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 11080
Study 23047956 — intervention group
Group type: EXPERIMENTAL
Intervention: Computerised cognitive behaviour therapy (CCBT)
Number of subjects: 88
Study 23047956 — intervention group
Group type: COMPARATOR
Intervention: Control condition (waitlist)
Number of subjects: 88
Study 23047956 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient ratings of treatment
Number of subjects: 88
Study 20669558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy (complete including external and primary iliac and lumboaortic chains up to the left renal vein)
Number of subjects: 0
Study 20669558 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphadenectomy
Number of subjects: 0
Study 19385464 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump (IABP) insertion
Number of subjects: 106
Study 16649862 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit theories of ability
Number of subjects: 0
Study 16649862 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 x 2 achievement goal framework
Number of subjects: 0
Study 16649862 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived competence
Number of subjects: 0
Study 12795541 — intervention group
Group type: EXPERIMENTAL
Intervention: Frame Model of Preadolescent Empowerment intervention
Number of subjects: 0
Study 11000331 — intervention group
Group type: EXPERIMENTAL
Intervention: PHHI patients
Number of subjects: 31
Study 11000331 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 31
Study 8838180 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (750 mg twice daily)
Number of subjects: 36
Study 8838180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 8470726 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrimethamine, sulfadiazine, and corticosteroids
Number of subjects: 149
Study 8470726 — intervention group
Group type: EXPERIMENTAL
Intervention: clindamycin, sulfadiazine, and corticosteroids
Number of subjects: 149
Study 8470726 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim, sulfamethoxazole and corticosteroids
Number of subjects: 149
Study 8470726 — intervention group
Group type: COMPARATOR
Intervention: untreated patients
Number of subjects: 149
Study 8470726 — intervention group
Group type: EXPERIMENTAL
Intervention: all patients
Number of subjects: 149
Study 8470726 — intervention group
Group type: EXPERIMENTAL
Intervention: pyrimethamine
Number of subjects: 149
Study 3769399 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose infusion at a rate of 1.1 mmol/min
Number of subjects: 14
Study 3769399 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 14
Study 30358731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal 0.50% DHEA (6.5 mg)
Number of subjects: 482
Study 26627728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 137
Study 26627728 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 137
Study 24872223 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake ranging from 600 to 2300 mg/d
Number of subjects: 40
Study 24872223 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium intake
Number of subjects: 40
Study 24872223 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alkaline phosphatase
Number of subjects: 40
Study 24872223 — intervention group
Group type: EXPERIMENTAL
Intervention: Other variables measured (urine N-telopeptide of type I collagen/creatinine ratio, Tanner score, serum parathyroid hormone, 25-hydroxyvitamin D, weight, height, body mass index)
Number of subjects: 40
Study 24324573 — intervention group
Group type: EXPERIMENTAL
Intervention: ART initiation
Number of subjects: 812
Study 20876929 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-mastectomy group (Group 1)
Number of subjects: 51
Study 20876929 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group 2)
Number of subjects: 51
Study 18929735 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional regimen (13 cycles with 21 days of treatment + 7 days without hormones)
Number of subjects: 59
Study 18929735 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-cycle regimen (4 extended cycles with 84 days of continuous administration of EE/DNG, followed by a hormone-free interval of 7 days)
Number of subjects: 59
Study 16622332 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric emptying time measured using half emptying time (T1/2) in GER-positive patients (grade 2)
Number of subjects: 108
Study 16622332 — intervention group
Group type: COMPARATOR
Intervention: Gastric emptying time measured using half emptying time (T1/2) in GER-negative patients
Number of subjects: 108
Study 16622332 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of reflux episodes
Number of subjects: 108
Study 12809074 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU; 120 mg daily, for 3 months)
Number of subjects: 48
Study 12809074 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 48
Study 11012954 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaging Method (IM)
Number of subjects: 45
Study 11012954 — intervention group
Group type: EXPERIMENTAL
Intervention: SmartNeedle (SM)
Number of subjects: 45
Study 11012954 — intervention group
Group type: EXPERIMENTAL
Intervention: Landmarks Method (LM)
Number of subjects: 45
Study 11012954 — intervention group
Group type: COMPARATOR
Intervention: All methods (IM, SM, LM)
Number of subjects: 45
Study 8781903 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 8 weeks
Number of subjects: 152
Study 8781903 — intervention group
Group type: COMPARATOR
Intervention: Triple therapy: bismuth subsalicylate 600 mg three times daily for 8 weeks, amoxicillin 500 mg twice daily, and tinidazole 1000 mg twice daily for the first 10 days
Number of subjects: 152
Study 8781903 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole group
Number of subjects: 152
Study 8781903 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy group
Number of subjects: 152
Study 8781903 — intervention group
Group type: COMPARATOR
Intervention: H. pylori positive patients
Number of subjects: 152
Study 8781903 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori negative patients
Number of subjects: 152
Study 1458662 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% amorolfine cream formulation applied to intact skin (n = 6)
Number of subjects: 12
Study 1458662 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% amorolfine cream formulation applied to stripped skin (n = 6)
Number of subjects: 12
Study 6419315 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyvalent pseudomonas vaccine (PEV‐01)
Number of subjects: 746